OWC Pharmaceutical Research Corp. - Consolidated Statements of Cash Flow	6 Months Ended
	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)
Cash flows from operating activities:
Net loss	$ (488,118)	$ (1,014,030)
Adjustments to reconcile net loss to net cash used in operating activites:
Amortization of debt discount	57,119	0
Depreciation expense	$ 4,825	$ 4,524
Common stock issued for services	0	241,170
Warrants issued for services	8,074	10,839
Changes in net assets and liabilities:
(Increase) decrease in accounts receivable	$ 4,098	$ 0
(Increase) decrease accounts receivable - related party	0	11,188
(Increase) decrease prepaid expenses	$ 27,056	$ 0
Increase (decrease) in accounts payable - related party	0	138
Increase (decrease) in accounts payable	$ 3,589	$ 35,763
Increase (decrease) in customer deposit	100,000	0
Increase (decrease) in accrued expenses	(190)	(40,697)
Net cash provided by (used in) operating activities	$ (271,949)	$ (751,105)
Cash flows from investing activities:
Purchase of equipment	(1,860)	(3,179)
Net cash used in investing activities	(1,860)	(3,179)
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 0	$ 90,000
Proceeds of debt borrowings	78,500	0
Payment of financing costs	(7,250)	0
Net cash provided by financing activities	$ 71,250	$ 90,000
Foreign currency translation	7,681	(5,608)
Change in cash	(194,878)	(699,893)
Cash at beginning of period	357,161	1,469,267
Cash at end of period	162,283	769,374
Non cash transactions:
Debt discount arising from derivatives	41,974	0